All Stocks/Healthcare/KRYS

Krystal Biotech, Inc.

KRYS
HealthcareBiotechnology Website
Price ChartPowered by TradingView
Ask about KRYSAI research agent
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Citadel
Ken Griffin
409K$100.91MNEW
Marshall Wace184K$45.30MNEW
Renaissance Technologies
Jim Simons (founder)
3K$813.6KNEW
D.E. Shaw
David Shaw
2K$519.7KNEW
Politicians who traded KRYSFrom Senate & House PTRs
PoliticianDateTypeAmount
Christopher L. Jacobs
NY
2022-12-12purchase$1k – $15k
About Krystal Biotech, Inc.

Krystal Biotech Inc. is a biotechnology company primarily focused on developing and commercializing gene therapy products for patients with rare dermatological conditions. Its innovative platform harnesses gene delivery technology to address unmet medical needs by developing a pipeline of products aimed at treating genetic skin diseases. Krystal Biotech’s key asset is its proprietary STAR-D platform, which allows for the non-viral delivery of therapeutic genes directly into the skin. This platform exemplifies the company's commitment to deploying cutting-edge science to improve patient outcomes. The company primarily impacts the healthcare and biotechnology sectors, seeking to revolutionize treatments for genetic disorders. Incorporated in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a significant role in advancing therapeutic options within the niche market of dermatological diseases, thereby positioning itself as a transformative player in gene therapy and medical research.

CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Employees
295
Quick Facts
Exchange–
SectorHealthcare
IndustryBiotechnology
Market Cap–
Key Dates

Earnings calendar coming soon. Subscribe to get notified when KRYS reports next.

Get earnings alerts →